A Systematic Overview of Chemotherapy Effects in Pancreatic Cancer

References

• Centre of Epidemiology. Cancer incidence of Sweden, 1999. Stockholm: The National Board of Health and Welfare.
   Google Scholar
• National Institute of Health, National Cancer Institute. 1987. Annual cancer statistics review, including cancer trends 1987: 190–8.
   Google Scholar
• Boyle P, Hsieh CC, Maisonneuve P, et al. Epidemiology of pancreatic cancer. Int .1- Pancreatol 1989; 5: 327–46.
   PubMedGoogle Scholar
• The Gastrointestinal Tumour Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: Flu-orouracil plus doxorubicin plus mitomycin-C and two regi-mens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 1986; 4: 1794-8. (C2/133)
   Google Scholar
• Rosewicz S, Wiedenman B. Pancreatic carcinoma. Lancet 1997; 349: 485–9.
   PubMed Web of Science ®Google Scholar
• Warshaw AL, Fernandez-del Castillo C. Pancreatic car-cinoma. N Engl J Med 1992; 326: 455-65. (L1)
   PubMedGoogle Scholar
• Bramhall SR, Neoptholemos J. Adjuvant pancreatic cancer. In: Neoptolemos JP, Lemine NR, eds. Pancreatic Cancer: Molecular and Clinical Advances. Blackwell Science Ltd, 1996: 288–307.
   Google Scholar
• Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 60: 2284–303.
   PubMed Web of Science ®Google Scholar
• Ihse L, Isaksson G. Pancreatic carcinoma: Diagnosis and treatment. Clin Gastroenterol 1984; 13: 961–84.
   PubMedGoogle Scholar
• Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer, assessment of prognosis by clinical presentation. Cancer 1985; 56: 397–402.
   Google Scholar
• Livingston EH, Reber HA. Cancer of the pancreas. Current Opin Gastroenterol 1991; 7: 739–43.
   Google Scholar
• Ozaki H. Improvement of pancreatic cancer treatment - From the Japanese Experience in the. Int J Pancreatol 12 1980s; 1992: 5–9.
   Google Scholar
• Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330: 313–8.
   PubMed Web of Science ®Google Scholar
• Raijman I, Levin B. Exocrine tumours of the pancreas. In: Go VLW, et al., eds. The pancreas: Biology, pathobiology and disease, 2nd Ed. New York: Raven Press, 1993: 899–912.
   Google Scholar
• Tsunoda T, Ura K, Eto T, et al. UICC and Japanese stage classification for carcinoma of the pancreas. Int J Pancreatol 1991; 8: 205–14.
   PubMedGoogle Scholar
• Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973; 73: 307–12.
   PubMed Web of Science ®Google Scholar
• Nagakawa T, Korishi I, Ueno K. The results and problems of extensive radical surgery for carcinoma of the head of pan-creas. Jpn J Surg 1991; 21: 262–7.
   Google Scholar
• Takahasi S, Ogata Y, Tsuzuki T. Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg 1994; 81: 1190–3.
   Google Scholar
• Wagner M, Friess H, Ruchler MW. Conservative versus radical resections of the pancreas. In: Neoptolemos JP, Lem-Me NR, eds. Pancreatic cancer: Molecular and clinical ad-vances. Blackwell Science Ltd, 1996: 248–70.
   Google Scholar
• Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13 560 patients with pancreatic cancer, and inci-dence of the disease, in the West Midlands: An epidemiologi-cal study. Br J Surg 1995; 82: 111–5.
   PubMed Web of Science ®Google Scholar
• Griffin JF, Smalley SR, Jewell W. Pattern of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 56–61.
   Google Scholar
• Westerdahl J, Andrén-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer-local or hepatic? Hepatogastroen-terology 1993; 40: 384–7.
   PubMedGoogle Scholar
• Splinter TA, Obertop H, Kok TC, et al. Adjuvant chemother-apy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomised pilot study. J Cancer Res Clin Oncol 1989; 115: 200-2. (P3/8)
   Google Scholar
• Bakkevold KE, Arnesjö B, Dahl O, et al. Adjuvant combina-tion chemotherapy (AMF) following radical resection of car-cinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703. (C2/61)
   Google Scholar
• Amano H, Takada T, Kato H, et al. Five-year results of a randomized study of postoperative adjuvant chemotherapy for resected pancreatic-biliary carcinomas. Proc Am Soc Clin Oncol 1999; 18: 1049. (C3/158)
   Google Scholar
• Gastrointestinal Tumour Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985; 56: 2563-8. (C2/157)
   Google Scholar
• Gastrointestinal Tumour Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of com-bined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-5. (C3/43)
   Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer: Adjuvant com-bined radiation and chemotherapy following curative resec-tion of pancreatic cancer. Cancer 1985; 120: 899-903. (C3/43)
   Google Scholar
• Klinkenbijl JHG, Sahmoud T, van Pel R, et al. Radiotherapy and 5-FU after curative resection for cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC and GITCCG. Eur J Cancer 1997; 33: Abstr 1239. (C3/119)
   Google Scholar
• Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil), and high dose radia-tion + 5-fluorouracil. Cancer 1981; 48: 1705-10. (C2/194)
   Google Scholar
• Gastrointestinal Tumour Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy fol-lowing curative resection for pancreatic cancer. Cancer 1987; 59: 2006-10. (P3/30)
   Google Scholar
• Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocar-cinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA 19-9 levels. Int J Radiat Oncol Biol Phys 1999; 44: 1039-46. (P2/29)
   Google Scholar
• Bruckner HW, Kalnicki S, Dalton J, et al. Survival after combined modality therapy for pancreatic cancer. J Clin Gastroenterol 1993; 16: 199-203. (P3/20)
   Google Scholar
• Foo ML, Gunderson LL, Nagomey DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation + 5-fluorouracil. Int J Ra-diat Oncol Biol Phys 1993; 26: 483-9. (P3/27)
   Google Scholar
• Jessup JM, Steele Jr G, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128: 559-64. (P2/16)
   Google Scholar
• Rich TA, Evans DB, Curley SA, et al. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol 1994; 5: 75-80. (L3)
   PubMedGoogle Scholar
• Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-37. (P1/142)
   Google Scholar
• Staley CA, Lee JE, Clearly KR, et al. Preoperative chemora-diation, pancreaticoduo-denectomy, and intraoperative radia-tion therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171: 118-24. (P2/39)
   Google Scholar
• Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduo-denectomy for pancreatic adenocarcinoma. Postoperative ad-juvant chemoradiation improves survival. Ann Surg 1997; 225: 621-36. (P1/174)
   Google Scholar
• Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16: 317-23. (P3/24)
   Google Scholar
• Prott FJ, Schonekaes K, Preusser P, et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 1997; 75: 597-601. (P3/32)
   Google Scholar
• Wagener DJ, Hoogenraad WJ, Rougier P, et al. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG Study. Eur J Cancer 1996; 32A: 1310-3. (P2/53)
   Google Scholar
• Regine WF, Ross AA. Adjuvant therapy for pancreatic can-cer: Back to the future. Int J Radiat Oncol Biol Phys 1998; 42: 59–63.
   PubMedGoogle Scholar
• Baker P. ESPAC-1 Trial. University of Birmingham/CRC Institute of Cancer Studies, Queen Elizabeth Hospital, Edg-baston, Birmingham B15, UK, 1995.
   Google Scholar
• Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancen results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281: 1589-91. (C3/40)
   Google Scholar
• Palmer KR, Kerr M, Knowles G, et al. Chemotherapy pro-longs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5. (C3/43)
   Google Scholar
• Glimelius B, Hoffman K, Sjödén P-0, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600. (C2/53)
   Google Scholar
• Andrén-Sandberg A, Holmberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vin-cristine, and CCNU. Scand J Gastroenterol 1983; 18: 609–12. (C3/47)
   Google Scholar
• Andersen JR, Friis-Moller A, Hancke S. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancre-atic cancer. Scand J Gastroenterol 1981; 16: 973-5. (C3/40)
   Google Scholar
• Frey C, Twomey P, Keehn R. Randomised study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Cancer Chemotherapy Study Group. Cancer 1981; 47: 27–31. (C2/152)
   Google Scholar
• Lionetto R, Pugliese P, Bruzzi P, et al. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995; 31A: 882-7. (M2/279)
   Google Scholar
• Schnall SF, Macdonald JS. Chemotherapy of adenocar-cinoma of the pancreas. Semin Oncol 1996; 23: 220-8. (L2)
   Google Scholar
• Ardalan B, Singh G, Silberman H. A randomised phase I and II study of short-term infusion of high dose fluorouracil with and without N-(phosphonacety1)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988; 6: 105 3–8. (P2/52)
   Google Scholar
• Crown J, Casper ES, Botet J. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancre-atic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6. (P3/22)
   Google Scholar
• DeCaprio J, Mayer R, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991; 9: 2128-33. (P2/42)
   Google Scholar
• Marsh RW, Manyam V, Bewsher C. Circadian rhythm modu-lated 5-FudR infusion with megace in the treatment of ad-vanced pancreatic cancer. J Surg Oncol 1994; 57: 25–9. (P3/18)
   Google Scholar
• Scheithauer W, Pfeffel F, Komek G. A phase II trial of 5-fluorouracil, leucovorin and recombinant alpha-2b-inter-feron in advanced adenocarcinoma of the pancreas. Cancer 1992; 70: 1864–6. (P2/32)
   Google Scholar
• Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976; 5: 777-93. (P3/44)
   Google Scholar
• Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int .1- Pancreatol 1990; 7: 209–22. (L2)
   PubMedGoogle Scholar
• Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabin in patients with advanced pancreatic cancer. Br J Cancer 1995; 73: 101-5. (P2/34)
   Google Scholar
• Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34. (P2/44)
   Google Scholar
• Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial in patients with 5-FU-refractory pancreatic cancer. Ann Oncol 1996; 7: 347-53. (P1/74)
   Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A ran-domised trial. J Clin Oncol 1997; 15: 2403-13. (C1/126)
   Google Scholar
• Cascinu S, Graziano F, Catalano G. Chemotherapy for ad-vanced pancreatic cancer: It may no longer be ignored. Ann Oncol 1999; 10: 105-9. (L2)
   Google Scholar
• Bitran JD, Desser RK, Kozloff MF. Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep 1979; 63: 2049–51. (P3/15)
   Google Scholar
• Bukowski RM, Schacter LP, Groppe CW. Phase II trial of 5-fluorouracil, adiamycin, mitomycin-C, and streptozotocin (FAM-S) in pancreatic adenocarcinoma. Cancer 1982; 50: 197–200. (P3/47)
   Google Scholar
• Smith FP, Hoth DF, Levin B, et al. 5-Fluorouracil, adri-amycin, and mitomycin-C (FAM) chemotherapy for ad-vanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014-8. (P3/39)
   Google Scholar
• Oster MW, Gray R, Panasci L, et al. for Cancer and Leukemia Group B. Chemotherapy for advanced pancreatic cancer. Cancer 1986; 57: 29-33. (C2/196)
   Google Scholar
• Kelsen D, Hudis C, Niedqwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin and 5-fluorou-racil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68: 965-9. (C2/82)
   Google Scholar
• Bukowski RM, Balcerzak SP, O'Bryan RM, et al. Ran-domised trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study. Cancer 1983; 52: 1577–82. (C2/115)
   Google Scholar
• Cullinan S, Moertel CG, Wieand, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990; 65: 2207-12. (C1/187)
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of ad-vanced pancreatic and gastric cancer: fluorouracil vs fluorou-racil and doxo-rubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253: 2061-7. (C1/146)
   Google Scholar
• Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorou-racil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 396–400. (C3/81)
   Google Scholar
• Topham C, Glees J, Rawson NS, et al. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mito-mycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 1991; 64: 179-81. (C2/69)
   Google Scholar
• Bukowski RM, Fleming TR, Macdonald JS, et al. Evaluation of combination chemotherapy and phase II agents in pancre-atic adenocarcinoma. A Southwest Oncology Group study. Cancer 1993; 71: 322-5. (C2/152)
   Google Scholar
• André T, Lotz JP, Boulenc C, et al. Phase II trial of 5-fluorouracil, leucovorin, and cisplatin for treatment of ad-vanced pancreatic adenocarcinoma. Ann Oncol 1996; 7: 173–8. (P2/52)
   Google Scholar
• Nicolson M, Webb A, Cunningham D, et al. Cisplatin and protracted venous infusion 5-fluorouracil (CF) - good symp-tom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 1995; 6: 801-4. (P1/63)
   Google Scholar
• Okusaka T, Okada S, Ishii H, et al. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cis-platin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol 1996; 26: 215-20. (P2/21)
   Google Scholar
• Rothman H, Cantrell JE, Lokich J Jr, et al. Continuous infusion 5-Fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program Study. Cancer 1991; 68: 264-8. (P2/56)
   Google Scholar
• Rougier P, Zarba JJ, Ducreux M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993; 4: 333-5. (P2/40)
   Google Scholar
• Rougier P, Ducreux M, Douillard JY, et al. Efficacy of 5FU cisplatin (FUP) compared with bolus 5FU (FU) in advanced pancreatic carcinoma (APC): A randomised trial from the French Anticancer Centres Digestive Group (FNLCCDG). Proc Am Soc Clin Oncol 1999; Abstr 1050. (C3/207)
   Google Scholar
• Gastrointestinal Tumour Study Group. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and b-2'-deoxythioguanosine as single agents against advanced mea-surable tumours of the pancreas. Cancer Treat Rep 1985; 69: 713-6. (C3/137)
   Google Scholar
• Gastrointestinal Tumour Study Group. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozo-tocin as single agents against advanced measurable adenocar-cinoma of the pancreas. Cancer Treat Rep 1985; 69: 417-20. (C3/156)
   Google Scholar
• Schein PS, Lavin PT, Moertel CG, et al. Randomised phase II clinical trial of adriamycin, methotrexate, and actimomycin-D in advanced measurable pancreatic carcinoma A Gastrointes-tinal Tumour Study Group report. Cancer 1978; 42: 19-22. (C3/60)
   Google Scholar
• Ekstrom K, Hoffman K, Linné T, et al. Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study. Oncol Reports 1998; 5: 931-4. (P2/26)
   Google Scholar
• Auerbach M, Wampler GL, Lokich JJ, et al. Treatment of advanced pancreatic carcinoma with a combination of pro-tracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic Oncology Program study. Ann Oncol 1997; 8: 439-44. (P2/47)
   Google Scholar
• Evans TRJ, Lofts FJ, Mansi JL, et al. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epiru-bicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260-4. (P2/35)
   Google Scholar
• Raderer M, Komek GV, Hejna MH, et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: A phase II study. Ann Oncol 1997; 8: 797-9. (P3/28)
   Google Scholar